Last reviewed · How we verify

Chemotherapy FOLFIRINOX, 6 cycles

University Hospital, Bordeaux · Phase 3 active Small molecule

Chemotherapy FOLFIRINOX, 6 cycles is a Combination chemotherapy regimen Small molecule drug developed by University Hospital, Bordeaux. It is currently in Phase 3 development for Metastatic pancreatic cancer, Locally advanced pancreatic cancer, Metastatic colorectal cancer.

FOLFIRINOX is a combination chemotherapy regimen that damages cancer cell DNA through multiple mechanisms, preventing replication and inducing cell death.

FOLFIRINOX is a combination chemotherapy regimen that damages cancer cell DNA through multiple mechanisms, preventing replication and inducing cell death. Used for Metastatic pancreatic cancer, Locally advanced pancreatic cancer, Metastatic colorectal cancer.

At a glance

Generic nameChemotherapy FOLFIRINOX, 6 cycles
SponsorUniversity Hospital, Bordeaux
Drug classCombination chemotherapy regimen
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

FOLFIRINOX combines four cytotoxic agents: 5-fluorouracil (5-FU) and leucovorin inhibit thymidylate synthase to disrupt DNA synthesis, irinotecan inhibits topoisomerase I to prevent DNA unwinding, and oxaliplatin creates DNA cross-links. Together, these agents attack cancer cells through complementary pathways, maximizing cytotoxic effect while allowing for dose optimization.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Chemotherapy FOLFIRINOX, 6 cycles

What is Chemotherapy FOLFIRINOX, 6 cycles?

Chemotherapy FOLFIRINOX, 6 cycles is a Combination chemotherapy regimen drug developed by University Hospital, Bordeaux, indicated for Metastatic pancreatic cancer, Locally advanced pancreatic cancer, Metastatic colorectal cancer.

How does Chemotherapy FOLFIRINOX, 6 cycles work?

FOLFIRINOX is a combination chemotherapy regimen that damages cancer cell DNA through multiple mechanisms, preventing replication and inducing cell death.

What is Chemotherapy FOLFIRINOX, 6 cycles used for?

Chemotherapy FOLFIRINOX, 6 cycles is indicated for Metastatic pancreatic cancer, Locally advanced pancreatic cancer, Metastatic colorectal cancer.

Who makes Chemotherapy FOLFIRINOX, 6 cycles?

Chemotherapy FOLFIRINOX, 6 cycles is developed by University Hospital, Bordeaux (see full University Hospital, Bordeaux pipeline at /company/university-hospital-bordeaux).

What drug class is Chemotherapy FOLFIRINOX, 6 cycles in?

Chemotherapy FOLFIRINOX, 6 cycles belongs to the Combination chemotherapy regimen class. See all Combination chemotherapy regimen drugs at /class/combination-chemotherapy-regimen.

What development phase is Chemotherapy FOLFIRINOX, 6 cycles in?

Chemotherapy FOLFIRINOX, 6 cycles is in Phase 3.

What are the side effects of Chemotherapy FOLFIRINOX, 6 cycles?

Common side effects of Chemotherapy FOLFIRINOX, 6 cycles include Neutropenia, Anemia, Thrombocytopenia, Diarrhea, Nausea/vomiting, Peripheral neuropathy.

Related